An observational study in Recurrent Implantation Failure, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the clinical efficacy of transcriptome-based endometrial receptivity analysis (tb-ERA) and investigate the molecular mechanisms of abnormal receptivity in young women with unexplained recurrent implantation failure (RIF).
Young women with recurrent implantation failure (RIF) will be prospectively recruited and classified based on their Window of Implantation (WOI) status. Clinical outcomes will be compared between patients undergoing personalized embryo transfer (pET) and those receiving standard transfer. Concurrently, endometrial tissues collected at P+3 and P+5 will undergo RNA sequencing to elucidate the molecular mechanisms underlying abnormal receptivity. Integrating these clinical and transcriptomic data, we aim to develop a clinical prediction model for displaced WOI and validate the efficacy of pET in improving pregnancy outcomes for this specific population.
ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will enroll women aged ≤ 35 years with a BMI of 18-25 kg/m². The RIF cohort includes patients with primary infertility and ≥ 3 failed transfers of high-quality embryos, further divided into the RIF-ERA group and the RIF non-ERA group (active comparator). The control group consists of patients undergoing their first IVF-ET cycle for tubal factor infertility, with no history of biochemical pregnancy or miscarriage. Patients with known causes of implantation failure will be excluded from all groups. All participants will provide written informed consent.
RIF Cohort - Inclusion Criteria
RIF Cohort - Exclusion Criteria
Control Group - Inclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RIF patients with tb-ERA and personalized embryo transfer
Other: tb-ERA and personalized embryo transfer
RIF patients receiving standard transfer
Non-RIF patients, receiving the first-time embryo transfer
tb-ERA and personalized embryo transfer
Ongoing pregnancy
Ongoing pregnancy is defined as viable pregnancy beyond 12 weeks' gestation.
Time frame: 12 weeks after embryo transfer
Clinical pregnancy
Pregnancy with ultrasound-confirmed intrauterine gestational sac(s)
Time frame: 6 to 8 weeks after embryo transfer
Implantation rate
The proportion of gestational sacs observed divided by the total number of embryos transferred
Time frame: 6 to 8 weeks after embryo transfer
Endometrial Receptivity Signature
The proportion of young RIF patients diagnosed with a displaced Window of Implantation (either pre-receptive or post-receptive) based on Endometrial Receptivity Analysis (ERA)
Time frame: Through ERA completion, an average of 1 month after sampling
Plan to share: Yes — De-identified individual patient data will be shared upon reasonable request to the corresponding author, subject to approval by the principal investigator and a signed data use agreement, following publication of the primary results. Data will be retained for a minimum of 5 years.
Supporting information: Study protocol
Time frame: Data will be retained for a minimum of 5 years.
Access criteria: De-identified individual patient data will be shared upon reasonable request to the corresponding author by email.
Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ShangHai Ji Ai Genetics & IVF Institute